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Abstract
Over the last few years, several new agents have been under evaluation in preclinical studies 
as well as in early clinical trials, and have shown promise in treating CLL. These treatments 
include  new  monoclonal  antibodies  (mAbs),  immunomodulating  agents,  novel  purine 
nucleoside analogs, Bcl-2 inhibitors and other agents. The most promising are a new mAbs 
targeted  CD20  molecule or  CD23, anti
flavopiridol,  and lenalidomide are  also  being evaluated both in pre
early clinical trials. However,  available therapies are only partially efficient and there is an 
obvious need to develop better strategies and new, more specific and active dr
Introduction: For  many  years,  alkylating  agents 
and  purine  nucleoside  analogs  (PNA)  have  been 
considered  the  drugs  of  choice  for  treatment  of 
CLL.
1,2 Combination  therapies  with  PNA  and 
cyclophosphamide  are  more  active  than 
monotherapy in terms of overall response rate (OR), 
complete  response  (CR)  and  progression  free 
survival  (PFS).
3-6 Recent  reports  suggest  that  the 
administration  of monoclonal  antibodies    (
can  significantly  improve  the  course  of 
present, there are two antibodies with great clinical 
value for patients with CLL. The first is rituximab 
(Rituxan,  Mabthera)  a  chimeric  anti
that  targets  CD20  antigen.
8 The  CD20  ant
expressed on almost all B-cells in patients with CLL 
but the intensity of expression appears to be lower 
than  in  patients  with  non  Hodgkin  lymphoma 
; Open Journal System 
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Over the last few years, several new agents have been under evaluation in preclinical studies 
as well as in early clinical trials, and have shown promise in treating CLL. These treatments 
new  monoclonal  antibodies  (mAbs),  immunomodulating  agents,  novel  purine 
2 inhibitors and other agents. The most promising are a new mAbs 
targeted  CD20 molecule  or  CD23, anti-CD40  mAbs  and anti-CD37  antibody.  Oblimersen, 
,  and lenalidomide  are  also being evaluated  both in pre-clinical studies and in 
early clinical trials. However,  available therapies are only partially efficient and there is an 
obvious need to develop better strategies and new, more specific and active drugs.
For  many  years,  alkylating  agents 
and  purine  nucleoside  analogs  (PNA)  have  been 
considered  the  drugs  of  choice  for  treatment  of 
Combination  therapies  with  PNA  and 
cyclophosphamide  are  more  active  than 
monotherapy in terms of overall response rate (OR), 
complete  response  (CR)  and  progression  free 
Recent  reports  suggest  that  the 
ibodies    (mAbs) 
can  significantly  improve  the  course of  CLL.
7 At 
present, there are two antibodies with great clinical 
value for patients with CLL. The first is rituximab 
a  chimeric  anti-CD20  mAb 
The  CD20  antigen  is 
cells in patients with CLL 
but the intensity of expression appears to be lower 
than  in  patients  with  non  Hodgkin  lymphoma 
(NHL).  Rituximab  in  conventional  doses  of  375 
mg/m
2 weekly for 4 doses has rather low activity in 
CLL.  However,  some  studies  suggest  that  higher 
doses are more effective than standard doses, used 
routinely  in  other  lymphoid  malignancies
second approved mAb is alemtuzumab (Campath
1H),  a humanized therapeutic mAb that recognizes 
the  CD52  antigen  expressed  on  normal  and 
neoplastic lymphoid cells.
10 This mAb is active in 
previously treated patients with CLL refractory to 
PNA.  Alemtuzumab  was  also  investigated  in 
previously  untreated  patients  with  this  leukemia. 
The results of a prospective randomized 
study  (CAM  307  trial)  comparing  high
chlorambucil  with  alemtuzumab  in  the  first
treatment  of  progressive  CLL  were  recently 
published.
11 The OR rate, CR rate,  and PFS time 
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Over the last few years, several new agents have been under evaluation in preclinical studies 
as well as in early clinical trials, and have shown promise in treating CLL. These treatments 
new  monoclonal  antibodies  (mAbs),  immunomodulating  agents,  novel  purine 
2 inhibitors and other agents. The most promising are a new mAbs 
CD37  antibody.  Oblimersen, 
clinical  studies and in 
early clinical trials. However,  available therapies are only partially efficient and there is an 
ugs.
(NHL).  Rituximab  in  conventional  doses  of  375 
weekly for 4 doses has rather low activity in 
L.  However,  some  studies  suggest  that  higher 
doses are more effective than standard doses, used 
in  other  lymphoid  malignancies.
9 The 
second approved mAb is alemtuzumab (Campath-
1H),  a humanized therapeutic mAb that recognizes 
pressed  on  normal  and 
This mAb is active in 
previously treated patients with CLL refractory to 
PNA.  Alemtuzumab  was  also  investigated  in 
previously  untreated  patients  with  this  leukemia. 
The results of a prospective randomized phase III 
study  (CAM  307  trial)  comparing  high-dose 
chlorambucil  with  alemtuzumab  in  the  first-line 
treatment  of  progressive  CLL  were  recently 
The OR rate, CR rate,  and PFS  time Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Table 1. Newer monoclonal antibodies potentially useful for chronic lymphocytic leukemia 
Abbreviations: CLL –chronic lymphocytic leukemia; NHL – non-Hodgkin lymphoma
were superior for alemtuzumab. Alemtuzumab is an 
effective  drug  in  CLL  patients  with  poor  risk 
cytogenetics,  such  as  deletions  in  17p.  However, 
alemtuzumab is ineffective  in  patients with bulky 
nodal  disease  (>5  cm).  In  previously  untreated 
patients with CLL, an OR rate of more than 80% 
can be achieved.
4,5
In  randomized  trials  the  combination  of 
rituximab  with  fludarabine  and cyclophosphamide 
(R-FC) demonstrated higher OR rate and CR rate, 
and  longer  PFS  time  than  F  C  in  previously 
untreated and relapsed/refractory CLL
12,13  Recently 
several  new  agents  have  been  explored  and  have 
shown  promise  in  CLL.
14,15 Novel  therapies  are 
being evaluated both in pre-clinical studies and in
early clinical trials. These treatments include new 
monoclonal  antibodies,  agents  targeting  the 
antiapoptotic  bcl-2  family  of  proteins,  receptors 
involved  in  mediating  survival  signals  from  the 
microenvironment,  antisense  oligonucleotides  and 
other agents.
Novel Monoclonal Antibodies: Over the last few 
years,  several  new  mAbs  and  have  been 
investigated in clinical trials in patients with CLL 
(Table 1 and Table 2).
16, 22
Ofatumumab  (HuMax-CD20;  Arzerra, 
GlaxoSmithKline/Genmab), is a second-generation, 
fully  human,  anti-CD20,  IgG1  mAb.
16-18
Ofatumumab recognizes  a different CD20 epitope 
to  rituximab.  Compared  with  rituximab, 
ofatumumab  has  similar  antibody-dependent 
cellular  cytotoxicity  (ADCC)  but  stronger 
complement-dependent  cytotoxicity (CDC)  and 
does  not  induce  cell  death  by  apoptosis.
17
Ofatumumab  has  been    investigated  in  phase  I/II 
study in 33 CLL patients with refractory or relapsed 
diseases.
16 In patients treated  with doses of 2000 
mg,  the  objective  response  rate  was  50%. 
Subsequently,  an  international  pivotal  trial  of 
ofatumumab  in  patients  with  CLL  refractory  to  
both fludarabine and alemtuzumab, or refractory to 
fludarabine with bulky lymphadenopathy has been 
undertaken (Hx-CD20-406 phase  III study).
18 The 
data from this study indicate that  the activity and 
safety  profile  of  ofatumumab  appeared  to  be 
consistent  with  the  prior  phase  I/II  study. The 
overall  reponse  rate  (ORR)  was  51%  for  the 
patients  with  CLL  refractory  to    fludarabine  and 
alemtuzumab and 44% for the patients refractoryto 
fludarabine  with  bulky  lymphadenopathy.  Median 
time  to next  CLL  therapy  was  9  months  and  8 
months,  respectively.  There  were  no  unexpected 
toxicities.  These  preliminary  results  demonstrate 
promising efficacy of ofatumumab monotherapy in 
a  heavily-pretreated  patients  with  fludarabine-
MoAb Antigen Antibody characteristics Clinical development
Ofatumumab (HuMax -CD20)  CD20 Human  IgG1- PhaseI/II in CLL and NHL
Veltuzumab (hA20, IMMU-106)  CD20 Human IgG1- PhaseI/II in NHL
GA-101 CD20 Humanized IgG1 PhaseI/II in NHL and CLL
Lumiliximab (IDEC-152) CD23 Chimeric macaque/human Phase III in CLL
Epratuzumab (hLL2)  CD22 Humanized IgG1- PhaseI/II in NHL
Galiximab (IDEC-114)  CD80 Chimeric human/macaque IgG1 Preclinical studies
HCD122(CHIR-12.12)  CD40 Human IgG1 Phase I in CLL
SGN-40  CD40 Humanized IgG1 Preclinical studies
TRU-016 (SMIP, CytoxB37G) CD37 Humanized fusion protein derived 
from anti-CD37 antibody Phase I in CLLMedit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Table 2. Clinical trials of new agents in chronic lymphocytic leukemia
Drug
Phase 
Of the 
study
No Patients 
characteristics
Response Median
response
duration
References OR CR
Ofatumumab I/II 33 Relapsed/
refractory 44% 0% PFS -106d Coiffier et al.(6)
Ofatumumab III
138
FA ref-59
BF ref-79
Relapsed/
refractory
FA ref-
58%
BFref -
47%
BFref-
1pt
FA ref-5.7m
BFref-5.9m Wierda et al. (8)
GA-101 I 13 Relapsed/
refractory 62% 0% NR Salles et al (10)
Lumiliximab I 46 Relapsed/ 
refractory 28%
* 0% NR Byrd et al.(14)
Oblimersen I/II 40 Relapsed/ 
refractory 8% 0% NR O’Brien et 
al.(18)
Flavopiridol II 42 Relapsed/  
refractory 45% 0% PFS 13 m Byrd et al.(23)
Lenalidomide II 45 Relapsed/  
refractory 47% 9% NR Chanan-Khan et 
al.(21)
Lenalidomide II 44 Relapsed/  
refractory
32% 7% 2pts progressed Ferrajoli et 
al.(22)
* Decrease in absolute lymphocyte count < 50%; NR – not reported; d-day; PFS – progression free survival; p.o. – orally; i.v. –
intravenously;  OR- overall  response;  CR- complete  response,  d  –day;  w  – week;  m  – months;  FA-ref  - fludarabine- and 
alemtuzumab-refractory ; BF-ref - fludarabine-refractory CLL with bulky lymphadenopathy
refractory CLL. Ofatumumab potentially represents 
an active treatment option with clinical benefit for 
patients  with  very  poor  prognosis who  have 
exhausted standard treatment options. 
GA-101 (RO5072759, Hoffman La Roche and 
Genentech)  is  a  novel,  third-generation,    type  II, 
anti-CD20,  fully humanized, IgG1  mAb, different 
from  rituximab.
19-21 GA-101  binds  with  high 
affinity  to  the  CD20  epitope  and,  as  a  result, 
induction of ADCC is 5-100 times greater than with 
rituximab. It  also  exhibits  superior  caspase–
independent  apoptosis  induction  than  rituximab. 
However, CDC activity is low.
21 In the phase I/IIa 
study GA-101 was administered as a singleagent to 
24  patients  with  CD20
+ malignant  disease,  who 
were  heavily  pretreated,  virtually  all  with  prior 
rituximab  and  for  whom  no  therapy of  higher 
priority was available.
20 Patients were treated with 
GA-101  at  doses  from  50  mg  to  2000  mg. The 
antibody  has  shown  a  similar  safety  profile  to 
rituximab and has demonstrated promising efficacy 
in this difficult-to-treat patient population.
Lumiliximab is a  genetically primatized,  macaque 
human  chimeric  anti-CD23  IgG1κ mAb 
investigated for the treatment of relapsed CLL.
22-25 
It induces ADCC and CDC, and enhances apoptosis 
when combined  with  current  or  emerging  CLL 
therapies including  chlorambucil,    fludarabine, 
alemtuzumab and  rituximab.
22 Byrd et al report the 
results  of  a  phase  1-2  study,  testing  the  R-FC 
regimen combined with lumiliximab in 31 patients 
with refractory/relapsed CLL.
25 The patients had a 
median of 2 prior therapies (range 1-10) and 61% of 
them  were  treated  with  fludarabine.  The  OR  rate 
was 65%, including 52% CRs. The median PFS was 
30.4 m (range 9.8-47.7m). In terms of CR rate, R-
FC+lumiliximab in this study compared favorably 
with  the  activity  of  R-FC  in  a  similar  patient 
population  (25%  CRs)  previously  reported  by 
Wierda  et  al.
26 However,  the  PFS  was  similar  in 
both trials: 29m and 28m, respectively. Importantly, 
the addition of lumiliximab to R-FC treatment did 
not increase its toxicity. Further randomized studies 
are ongoing to confirm that the use of lumiliximab 
in  combination  with  R-FC  is  a  more  effective 
treatment regimenfor the eradication of CLL.
TRU-016  is  an  intravenously  administered  anti-
CD37 IgG fusion protein for the potential treatment 
of  B-cell  malignancies,  including  CLL and  non-
Hodgkin's  lymphoma  (NHL).
27,28 TRU-016  was 
created by humanizing SMIP-016, a mouse/human 
chimeric protein with preclinical antitumor activity 
against  lymphoid  malignancies.  TRU-016  was 
active in mouse human B-cell tumor xenograft NHL 
models.  In  addition,  TRU-016  demonstrated 
synergistic  or  additive  activity  in  NHL  cells  in 
combination  with  rituximab,  rapamycin, 
doxorubicin and bendamustine. In a phase I clinical 
trial in refractory or relapsed patients with CLL or 
small lymphocytic lymphoma, TRU-016 was well 
tolerated  with  clinical  benefit  and  a  reduced Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
absolute lymphocyte count observed in all cohorts 
above the 0.1-mg/kg dose.
28
In  addition,  several  other  mAbs  directed  against 
lymphoid  cells have  been  recently  developed  and 
investigated in preclinical studies and clinical trials
(Table 1).
14 These treatments include epratuzumab, 
galiximab and anti-CD40 mAbs.
Novel Purine Nucleoside Analogs: Recently three 
novel PNAs: clofarabine (CAFdA), nelarabine (ara-
G) and forodesine (immucillin H, BCX-1777), have 
been  synthesized  and  introduced  into  clinical 
trials.
29,30
Forodesine (Immucillin H) is a type of immucillin: 
a 9-deazanucleoside analogue which acts as a purine 
nucleoside  phosphorylase  (PNP) inhibitor.
29
Immucillins have a structure based on ”nitrogen in 
the ring” D-ribofuranosyl C-glycosidic analogues of 
natural nucleosides. Forodesine is the most potent 
member  of  this  group  (Figure  1).
29 Recently, 
preliminary  studies  have  been  initiated  into  the 
efficacy of forodesine in the treatment of patients 
with advanced and refractory CLL. 
Immunomodulating  Agents:  Immunomodulating 
agents  are  a  new  class  of  drugs  that  change 
expression  of  various  cytokines  and  costimulate 
immune  effector  cells.
31-35  Thalidomide  and  its 
derivative  lenalidomide  (Revlimid;  Cellgene)  are 
immunomodulating  agents  with  possible 
antiangiogenic properties which modulate cytokine 
activity in the tumor microenvironment. The exact 
mechanism of action of this drug remains unknown 
although  antiangiogenic  and  immunomodulatory 
effects  through  cytokine  modulation  in  the  tumor 
microenvironment  have  been  reported.
  
Lenalidomide is a less toxic analog of thalidomide, 
and in vitro has more potent activity than the parent 
compound  (Figure  1).
31 This  agent  has  been 
investigated in patients with relapsed/refractory and 
previously  untreated  CLL.  Chanan-Khan  et  al.
32   
reported the anti-leukemic effects of  lenalidomide 
in  45  CLL  patients  with  relapsed  or  refractory 
disease. The drug was administered orally at a dose 
of  25  mg  once  a  day  for  21  days  on  a  28-day 
schedule.  Major  responses  were  observed  in  21 
patients  (41%),  with  4  CR  (9%),  and  17  (38%) 
achieving a PR in the intent-to treat analysis. The 
most  common  non-hematologic  adverse  events 
were  fatigue  (83%)  and  flare  reaction  (58%). 
Ferrajoli et al.
35 presented the results of a phase II 
study in which lenalidomide was started with lower 
doses of 10 mg per day by continuous daily dosing, 
with dose escalation up to 25 mg, based on patient 
tolerability and response. Three out of 44 patients 
(7%) achieved a CR and OR rate was 32%. Thirteen 
patients (30%) developed tumor flare reaction. 
Recently,  Chen  et  al.
34 have  reported 
preliminary  results  from  a  phase  II  study  of 
lenalidomide used as  a  single-agent in  previously 
untreated, symptomatic CLL. The starting dose for 
lenalidomide  was  initially  10mg  po  daily  with 
weekly 5mg dose escalations to the target dose of 
25mg daily x 21 days every 28 day cycle. All 17 
patients, evaluable for response, have achieved PR 
(65%)  or  stable  disease  (35%).  Responses  were 
reached  at  a  median  of  4  cycles  (range  2–15). 
Preliminary results from this phase II study suggest 
that  lenalidomide  has  a  significant  activity  and 
acceptable  toxicity  in  previously  untreated  CLL 
patients.  However,  a  conservative  low-dose, 
continuous  dosing  regimen  and  careful  safety 
monitoring are suggested to obtain a safer and more 
effective use of this drug.
Ferrajoli  et  al.
35 evaluated  the  efficacy  and 
tolerability  of  lenalidomide  as  initial  therapy  of 
older patients with CLL. All patients received the 
drug at the dose of 5 mg daily for the first 56 days 
and then the dose could be increased up by 5 mg 
every 28 days to reach a maximum dose of 25mg 
daily. Nineteen (54%) patients achieved a PR and 
14 patients (40%) had stable disease. These results 
indicate  that lenalidomide  given  as  continuous 
therapy at a start dose of 5 mg followed by slow 
dose escalation is safe and well-tolerated in initial 
therapy of elderly patients with CLL. 
Bcl-2  Family  Inhibitors:  Oblimersen  (Genasense, 
Bcl-2  antisense,  G3139)  is  a  synthetic,  18-base, 
single  strand  phosphorothioate  DNA 
oligonucleotide  designed  to  down-regulate  Bcl-2
mRNA  expression.
36,37 The  agent  recognizes  the 
first  six  codons  of  Bcl-2,  forming  a  DNA/RNA 
complex  that  inhibits  translation  of  the    protein. 
Oblimersen  consequently  reduces  levels  of  Bcl-2 
expression, reduces cell viability, increases activity 
of  pro-apoptotic  mechanisms,  reduces  tumor  size 
and enhances anticancer drug activity. The addition 
of oblimersen to chemotherapy with fludarabine and 
cyclophosphamide  (FC)  produced  a  significant 
increase  in  the  number  of  durable  remissions  in 
patients  with  relapsed  or  refractory  CLL.
37 In 
addition,  the  updated  analysis  showed  that  in 
relapsed/refractory CLL, oblimersen combined with 
FC offers patients who achieve CR or PR , as well 
as those who have fludarabine-sensitive disease, a 
significant survival benefit.
37 This agent should be 
further  evaluated  in previously  untreated  patients.Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Figure 1. Chemical structures of new drugs, potentially useful for chronic lymphocytic leukemia.
Therapeutic modulation of the Bcl-2 pathway may 
represent a new  treatment option in CLL. 
Obatoclax  (GX15-070)  is  a  hydrophobic 
molecule,  developed as  a  Bcl-2 family  antagonist 
(Figure  1).
38,39 This  agent  inhibits  several  anti-
apoptotic  Bcl-2  family  proteins  including  Bcl-XL, 
Bcl-2,  Bcl-w, BCL-B, A-1  and  Mcl-1.  Moreover, 
obatoclax can promote the release of cytochrome C 
from  mitochondria  isolated  from  leukemia  cells. 
Apoptosis induced by this agent was preceded by 
the release of Bak from Mcl-1, liberation of Bim 
from both Bcl-2 and Mcl-1 and the formation of an 
active Bak/Bax complex.
38 O’Brien et al.
40 reported 
the results of a phase I trial of obatoclax in CLL 
patients. The drug was administered to patients with 
advanced  CLL  both  as  a  1-hr  infusion  at  doses 
ranging  from  3.5  to  14  mg/m
2,  and  as  a  3-hr 
infusion at doses between 20 to 40 mg/m
2 every 3 
weeks.  One  (4%)  of  26  patients  achieved  a  PR. 
Patients  with  anemia  (3/11)  or  thrombocytopenia 
(4/14)  experienced  improvements  in  hemoglobin 
and platelet counts. Circulating lymphocyte counts 
were  reduced  in  18/26  patients  with  a  median 
reduction of 24%. The most frequent adverse event 
was somnolence and euphoria occurring during the 
infusion or shortly afterwards.
ABT-263 is another small molecule that binds 
with  high  affinity  to  several  anti-apoptotic  Bcl-2 
family proteins including Bcl-XL, Bcl-2 and Bcl-w 
but  not  Mcl-1  or  A1(Figure  1).
42,42 Oral 
bioavailability  of  ABT-263  is  20%  to  50% 
depending on the formulation. The phase I/IIa trial 
was  performed  in  patients  with  refractory  or 
relapsed  lymphoid  malignancies.
42 ABT-263  was 
administered at doses of 10, 20, 40, 80 and 160 mg 
to  17  subjects  who  took  part  in  the  study.  Two 
patients with bulky CLL/SLL in the 40 and 160 mg 
cohorts had 95% and 64% tumor reductions    
AT-101  ((-)Gossypol,  Tw-37)  is    another 
orally-available  small  molecule  that  mimics  the 
BH3 domain of cellular Bcl-2 and interferes with 
the function of prosurvival  Bcl-2 proteins (Figure 
1).
43 It  is  a  derivative  of  a  natural    product  -
gossypol - capable of binding to Bcl-2, Bcl-XL and 
Mcl-1,  attenuating  their  anti-apoptotic  influence. 
AT-101 was investigated together with rituximab in 
a  phase  II  study  in  refractory  CLL  patients  by 
Castro et al.
44 AT-101 was administered at a dose of 
30 mg/d for 21 or 28 days during each of 28- day 
cycles. Rituximab was administered at 375 mg/m
2
in  12  doses.  The  OR  rate  was  38%,  grade  1-2 
gastrointestinal  toxicity  occurred  in  11  of  12 
patients.  
Protein  Kinase Inhibitors:  Flavopiridol, 
(Alvocidib,  HMR-1275,  MDL-107826A,  NSC-
649890) is a synthetic derivative of the flavonoid 
rohitukine (Figure 1).
45 Flavopiridol was originally 
described as an inhibitor of cyclin-dependent kinase 
and other protein kinases because of its interaction 
with adenosine triphosphate binding sites. Recently 
presented up-dated results confirm  that flavopiridol 
induces  durable  responses  in  heavily  pretreated, 
relapsed CLL patients with bulky lymphadenopathy 
(>5cm) and poor-riskcytogenetic features.
45Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
Roscovitine  is  a  purine  analog  that  competes 
with  ATP  for  a  binding  site  on  cyclin-dependent 
kinases (CDKs) (Figure 1).
46 This small molecule 
inhibits  CDK-induced  apoptosis  in  isolated  CLL 
cells by caspase activation and modulation of Bcl-2 
family  proteins.
46 Roscovitine  and  its  pure  R-
enantiomer CYC202 (R-Roscovitine, Seliciclib) are 
independent  of  p53  activation  or  defects  in  p-53 
dependent  pathways.  CYC2002  was  shown  to  be 
highly effective in a panel of 19 human tumor cell 
lines and a human tumor xenograft model.
46 In the 
CLL  cell  culture,  CYC 202  displays reduced and 
delayed  apoptosis.  Moreover,  this  agent  causes  a 
significant down-regulation of genes involved in the 
transcription, translation, survival and DNA repair 
of CLL cells.
46 CYC202 is a promising candidate 
drug for clinical tests alone or in combination with 
other agents in relapsed CLL.    
Conclusions: Currently available therapies are only 
partially efficient in CLL, exposing an obvious need 
to  develop  new,  more  specific  and  active  drugs. 
Recently, several new drugs have been developed 
and are being evaluated in clinical trials (Table 2).  
Further studies should elucidate the role of  these 
new  agents  and  their  combinations  in  the 
management of CLL.
Acknowledgement:  The  work  was  supported  by  the 
Foundation  for  Development  of  Diagnostics  and 
Therapy,  Warsaw,  Poland  and  by  the  grant  from  the 
Medical University of Lodz No. 503-1093-1.    
References:
1. Dighiero  G,  Hamblin  TJ.  Chronic  lymphocytic 
leukaemia. Lancet. 2008;371(9617):1017-29.
2. Robak  T,  Jamroziak  K,  Robak  P.  Current  and  emerging 
treatments  for  chronic lymphocytic  leukaemia.  Drugs. 
2009;69(17):2415-49.
3. Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus 
cyclophosphamide  versus  fludarabine  alone  in  first-line 
therapy  of  younger  patients  with  chronic  lymphocytic  
leukemia. Blood  2006; 107: 885-91.
4. Flinn IW, Neuberg DS, Grever MR et al. Phase III trial of 
fludarabine  plus  cyclophosphamide  compared  with 
fludarabine for patients with previously untreated chronic 
lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. 
Oncol. 2007; 25:  793-8.
5. Catovsky D, Richards S, Matutes  E et  al. Assessment of 
fludarabine  plus  cyclophosphamide  for  patients  with 
chronic  lymphocytic  leukemia  (the  LRF  CLL4  Trial):  a 
randomised controlled trial. Lancet 2007; 370: 230-9.
6. Robak T, Blonski JZ, Gora-Tybor J, et al. Cladribine alone 
and  in  combination  with  cyclophosphamide    or 
cyclophosphamide  plus  mitoxantrone  in  the  treatment  of 
progressive  chronic  lymphocytic  leukemia:  report  of 
prospective,  multicenter,  randomized    trial  of  the  Polish  
Adult  Leukemia  Group  (PALG  CLL2).  Blood  2006;108: 
473-9. 
7. Robak T. Monoclonal antibodies in the treatment of chronic 
lymphoid leukemias. Leuk. Lymphoma. 2004; 45: 205-19.
8. Onrust  SV,  Lamb  HM,      Balfour  JA.  Rituximab.  Drugs
1999; 58: 79-88.
9. O’Brien SM, Kantarjian H, Thomas DA  et al. Rituximab 
dose-escalation  trial  in  chronic  lymphocytic  leukemia.  J. 
Clin. Oncol. 2001; 19: 2165-70.
10. Robak  T.  Alemtuzumab  for  B-cell  chronic  lymphocytic 
leukemia. Expert Rev. Anticancer Ther. 2008; 8:1033-51. 
11. Hillmen  P,  Skotnicki  A,  Robak  T,  et.  al. Alemtuzumab 
compared  with  chlorambucil  as  first  line  therapy  for 
patients  requiring  treatment  for  chronic  lymphocytic 
leukemia.. J. Clin. Oncol . 2007; 25: 5616-23
12. Hallek  M,  Fingerle-Rowson  G,  Fink  AM,  et  al. 
Immunochemotherapy  with  fludarabine  (F), 
cyclophosphamide  ©,  and  rituximab  ®  (FCR)  versus 
fludarabine and cyclophosphamide (FC) improves response 
rates  and  progression-free  survival  (PFS)  of  previously 
untreated patients (pts) with advanced chronic lymphocytic 
leukemia (CLL). Blood  2008; 112 : 125 (Abstract 325).
13. Robak T, Dmoszynska A, Solal-Céligny P, et al Rituximab 
plus  fludarabine  and  cyclophosphamide  prolongs 
progression-free  survival  compared  with  fludarabine  and 
cyclophosphamide  alone  in  previously  treated  chronic 
lymphocytic leukemia. J Clin Oncol. 2010 ;28:1756-65.
14. Robak T. Novel monoclonal antibodies for the treatment of 
chronic lymphocytic leukemia. Curr Cancer Drug Targets
2008;8:156-71.
15. Robak  T.  Novel  drugs  for  chronic  lymphoid  leukemias: 
mechanism  of  action  and  therapeutic  activity.  Curr  Med 
Chem. 2009;16:2212-34.
16. Coiffier B, Lepretre S,  Pedersen  LM, et al. Safety and 
efficacy  ofofatumumab,  a  fully  human  monoclonal  anti-
CD20 antibody, in patients with relapsed or refractory B-
cell  chronic  lymphocytic  leukemia.  A  phase  I-II  study. 
Blood 2008; 11:1094-1100. 
17. Robak T. Ofatumumab, a human monoclonal antibody for
lymphoid  malignancies  and  autoimmune  disorders.  Curr 
Opin Mol Ther 2008;10: 294-309.
18. Wierda WG, Kipps TJ, Mayer J et al  Hx-CD20-406 Study 
Investigators.  Ofatumumab  as  single-agent  CD20 
immunotherapy  in  fludarabine-refractory  chronic 
lymphocytic leukemia. J Clin Oncol. 2010;28:1749-55. 
19. Umana P, Moessner E, Bruenker P, et al. GA101,   a novel 
humanized  type  II  CD20  antibody  with  glycoengineered   
Fc and   anhanced cell death induction, exhibits superior 
anti-tumor efficacy and   superior tissue B cell depletion in 
vivo. Blood 2007;110: 694a (Abstract 2348). 
20. Salles,GA, Morschhauser F, Cartron G, et al. A Phase I/II 
study  of  RO5072759  (GA101)  in  patients  with 
relapsed/refractory  CD20
+ malignant  disease.  Blood  
2008;112: 93 (abstract 234).
21. Robak  T.  GA-101,  a third-generation,  humanized  and 
glyco-engineered anti CD20 mAb for the treatment of B-
cell  lymphoid  malignancies.  Curr  Opin  Investig  Drugs
2009;10:588-96.
22. Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd 
J.  Mediation  of  apoptosis  by  and  antitumor  activity  of 
lumiliximab  in  chronic  lymphocytic  leukemia  cells  and 
CD23+ lymphoma cell lines. Blood 2008; 11: 1594-602.
23. Robak T. Improving FCR immunochemotherapy in CLL. 
Blood. 2010; 115(3):437-8. 
24. Byrd  JC, O’Brien SO, Flinn  IW,  et al. Phase 1 study of 
lumiliximab  with  detailed  pharmacokinetic  and 
pharmacodynamic measurements in patients with relapsed 
or  refractory  chronic  lymphocytic  leukemia.  Clin  Cancer 
Res 2007; 13 (15 Pt 1): 4448-55.
25. Byrd  JC,  Kipps  TJ,  Flinn  IW,  et  al.  Phase  ½  study  of 
lumiliximab combined with fludarabine, cyclophosphamide 
and rituximab in patients with relapsed or refractory chronic 
lymphocytic leukemia. Blood 2010; 115:489-95.Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
26. Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy 
with  fludarabine,  cyclophosphamide  and  rituximab  for 
relapsed and refractory  chronic lymphocytic  leukemia. J 
Clin Oncol 2005; 23: 4070-4078.  
27. Robak T, Robak P, Smolewski P. TRU-016, a humanized 
anti-CD37 IgG fusion protein for the potential treatment of 
B-cell  malignancies.  Curr  Opin  Investig  Drugs.  2009 
;10:1383-90.
28. Andritsos L, Furman R, Flinn IW, et al. A phase I trial of 
TRU-016,  an  anti-CD37  small  modular 
immunopharmaceutical (SMIP) in  relapsed and refractory 
CLL. Am  Soc Clin Oncol Ann Meet. 2009; 45: Abs 3017.
29. Korycka A, Błoński JZ, Robak T. Forodesine (BCX-1777, 
Immucillin  H)--a  new  purine  nucleoside  analogue: 
mechanism of action and potential clinical application. Mini 
Rev Med Chem. 2007; 7:976-83.
30. Robak T, Lech-Maranda E, Korycka A, Robak E. Purine 
nucleoside  analogs  as  immunosuppressive  and 
antineoplastic  agents:  mechanism  of  action  and  clinical 
activity. Curr Med Chem. 2006;13:3165-89.
31. Chanan-Khan A, Porter CW. Immunomodulating drugs for 
chronic lymphocytic leukemia. Lancet  Oncol 2006; 7: 80-
8. 
32. Chanan-Khan  A,  Miller  KC,  Musial  L,  et  al.  Clinical 
efficacy  of  lenalidomide  in  patients  with  relapsed  or 
refractory chronic lymphocytic leukemia: results of a phase 
II study. J Clin Oncol 2006; 24: 5343-9.
33. Ferrajoli  A,  Lee  BN,  Schlette  EJ,  et  al. Lenalidomide  
induces complete and  partial remissions in patients with 
relapsed  and  refractory    chronic    lymphocytic  leukemia. 
Blood. 2008;111: 52-61. 
34. Chen  C,    Paul  H,  Xu  W,  et  al.    A  phase  II  study  of 
lenalidomide in previously untreated, symptomatic chronic 
lymphocytic  leukemia  (CLL)  [Abstract  44].  Blood 
2008;112  : 23.
35. Ferrajoli A, O’Brien S, Wierda W  et al. Lenalidomide as 
initial  treatment  of  elderly  patients  with  chronic 
lymphocytic  leukemia  (CLL)[  Abstract  45].  Blood  
2008;112 (11): 23. 
36. O'Brien SM,  Cunningham CC, Golenkov AK, et al. Phase I 
to  II  multicenter  study  of  oblimersen  sodium,  a  Bcl-2 
antisense oligonucleotide in patients with advanced chronic 
lymphocytic  leukemia. J Clin Oncol  2005; 23:7697-702.
37. O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki AB, 
Koziner B, Chanan-Khan AA, Seymour JF, Gribben J, Itri 
LM, Rai KR. 5-year survival in patients with relapsed or 
refractory chronic lymphocytic leukemia in a randomized, 
phase III trial of fludarabine plus cyclophosphamide with or 
without oblimersen. J Clin Oncol. 2009;27:5208-12. 
38. Konopleva M, Watt J, Contractor R, et al. Mechanisms of 
antileukemic activity of the novel bcl-2 homology domain-3 
mimetic GX15-070 (obatoclax). Cancer Res 2008; 68 (9) : 
3413-20.
39. Nguyen  M,  Marcellus  RC,  Roulston  A,  et  al.  Small 
molecule  obatoclax  (GX15-070)  antagonizes  MCL-1  and 
overcomes MCL-1-mediated  resistance to apoptosis.  Proc 
Natl Acad Sci U S A  2007; 104: 19512-7.
40. O'Brien SM, Claxton DF, Crump M,  Faderl  S, Kipps  T, 
Keating  MJ,  Viallet  J,  Cheson  BD.  Phase  I  study  of 
obatoclax mesylate (GX15-070), a small molecule pan-Bcl-
2  family  antagonist,  in  patients  with  advanced  chronic 
lymphocytic leukemia. Blood. 2009 ;113:299-305.
41. Tse C, Shoemaker AR, Adickes J, et al.  ABT-263: a potent 
and orally bioavailable bcl-2 family inhibitor. Cancer Res 
2008; 68: 3421-8.
42. Wilson WH, Tulpule A, Levine AM, et al.  A  phase  1/2a 
study evaluating the safety, pharmacokinetics and efficacy 
of  ABT-263  in    subjects  with  refractory  or  relapsed 
lymphoid malignancies [Abstract 1371]. Blood 2007; 110: 
412a.
43. Paoluzzi L, Gonen M, Gardner JR, et al. Targeting Bcl-2 
family members with the BH3 mimetic AT-101 markedly 
enhances the therapeutic effects of chemotherapeutic agents 
in in vitro and in vivo models of B-cell lymphoma. Blood  
2008; 111: 5350-8.
44. Castro J, Olivier L, Rober AA, et al. A Phase II, open label 
study of AT-101 in combination with rituximab in patients 
with relapsed or refractory  chronic lymphocytic leukaemia 
[Abstract 2838]. Blood 2006; 108: 803a.
45. Byrd  JC,  Lin  TS,  Dalton,  JT,  et  al.  Flavopiridol  
administered using a pharmacologically derived schedule is 
associated  with  marked  clinical  efficacy  in  refractory, 
genetically high-risk chronic lymphocytic leukemia. Blood 
2007; 109: 399-404. 
46. Alvi AJ, Austen B, Weston VJ, et al. Novel CDK inhibitor, 
CYC202  (R-roscovitine),  overcomes  the  defect  in  p53-
dependent apoptosis in B-CLL by down-regulation of genes 
involved  in  transcription  regulation  and  survival.  Blood 
2005; 105: 4484-91.